IPO News Archive
Biotech company BioHeart amends IPO terms

2/13/08


In the latest of a series of revisions, BioHeart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, amended the terms for its IPO. The company now plans to offer 1.1 million shares at a range of $5.00-$5.50. In September, the company filed for an offering of 3.6 million shares at a range of $14-$16. Dawson James Securities is the sole underwriter on the deal.

View IPO Profile: BHRT         
Related Links: Recently Filed IPOs
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest